Corresponding to the FDA made easy! Cut and copy.

*When corresponding to the FDA about your written comments on use of the 
smallpox vaccine trial on 2-5 year old children, please use the address below 
and it is important to insert in the subject the docket number:

Address:    [email protected]
Subject:     RE: Docket No. 02N–0466

Your comment can simply say  "I DO NOT support the smallpox vaccine study, 
Docket No. 02N–0466."

Also remember the FDA WORKS for US!

DATES: To be considered, written or electronic comments on the proposed 
research must be received on or before 4:30 p.m. December 2, 2002.
ADDRESSES: Submit written comments to the Dockets Management Branch 
(HFA–305), Docket Number 02N–0466, Food and Drug Administration, 5630 Fishers 
Lane, Room 1061, Rockville, MD 20852. Submit electronic comments to 
http://www.fda.gov/dockets/ecomments. All comments should be identified with 
the docket number found in brackets in the heading of this document. Received 
comments may be viewed on the FDA Web site at: http://www.fda.gov/ohrms/ 
dockets/dockets/02n0466/02n0466.htm or may be seen in the Dockets Management 
Branch between 9 a.m. and 4 p.m., Monday through Friday.

~ ~ ~ ~ DETAILS ~ ~ ~ ~ ~ ~ 
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Office of Public Health and Science
and Food and Drug Administration
[Docket No. 02N–0466]
Solicitation of Public Review and
Comment on Research Protocol: A
Multicenter, Randomized Dose
Response Study of the Safety, Clinical
and Immune Response of Dryvax
Administered to Children 2 to 5 Years
of Age
AGENCY: Office of Public Health and
Science and Food and Drug
Administration, HHS.
ACTION: Notice.
SUMMARY: The Office for Human
Research Protections (OHRP), Office of
Public Health and Science, Department
of Health and Human Services (HHS)
and the Food and Drug Administration
(FDA), HHS are soliciting public review
and comment on a proposed research
protocol entitled ‘‘A Multicenter,
Randomized Dose Response Study of
the Safety, Clinical and Immune
Response of DryvaxAdministered to
Children 2 to 5 Years of Age.’’ The
proposed research would be supported
by a contract awarded by the National
Institutes of Health (NIH) and
conducted under an Investigational New
Drug Application (IND) filed with the
FDA. Public review and comment is
solicited regarding the proposed
research protocol pursuant to the
requirements of HHS regulations at 45
CFR 46.407 and FDA regulations at 21
CFR 50.54.
DATES: To be considered, written or
electronic comments on the proposed
research must be received on or before
4:30 p.m. December 2, 2002.
ADDRESSES: Submit written comments
to the Dockets Management Branch
(HFA–305), Docket Number 02N–0466,
Food and Drug Administration, 5630
Fishers Lane, Room 1061, Rockville, MD
20852. Submit electronic comments to
http://www.fda.gov/dockets/ecomments.
All comments should be identified with
the docket number found in brackets in
the heading of this document. Received
comments may be viewed on the FDA
Web site at: http://www.fda.gov/ohrms/
dockets/dockets/02n0466/02n0466.htm
or may be seen in the Dockets
Management Branch between 9 a.m. and
4 p.m., Monday through Friday.
FOR FURTHER INFORMATION CONTACT: Dr.
Leslie K. Ball, Office for Human
Research Protection, The Tower
Building, 1101 Wootton Parkway, Suite
200, Rockville, MD 20852; telephone301–496–7005; fax 301–402–0527; e-mail:
[email protected]; or Ms.
Patricia M. Beers Block, Office for Good
Clinical Practice, OSHC, Office of the
Commissioner, Food and Drug
Administration, 5600 Fishers Lane, HF–
34, Rockville, MD 20857; telephone
301–827–3340; fax 301–827–1169; e-mail:
[email protected].
SUPPLEMENTARY INFORMATION: All
studies conducted or supported by HHS
which are not otherwise exempt and
which propose to involve children as
subjects require Institutional Review
Board (IRB) review in accordance with
the provisions of HHS regulations at 45
CFR part 46, subpart D. Under FDA’s
Interim Final Rule effective April 30,
2001 (21 CFR part 50, subpart D), FDA
adopted similar regulations to provide
safeguards for children enrolled in
clinical investigations of FDA-regulated
products.
Pursuant to HHS regulations at 45
CFR 46.407 and FDA regulations at 21
CFR 50.54, if an IRB reviewing a
protocol conducted or supported by
HHS for a clinical investigation
regulated by FDA does not believe that
the proposed research or clinical
investigation involving children as
subjects meets the requirements of HHS
regulations at 45 CFR 46.404, 46.405, or
46.406, and FDA regulations at 21 CFR
50.51, 50.52, or 50.53, respectively, the
research or clinical investigation may
proceed only if the following conditions
are met: (a) The IRB finds and
documents that the research or clinical
investigation presents a reasonable
opportunity to further the
understanding, prevention, or
alleviation of a serious problem
affecting the health and welfare of
children; and (b) the Secretary (HHS)
and the Commissioner (FDA),
respectively, after consultation with a
panel of experts in pertinent disciplines
(for example: science, medicine,
education, ethics, law) and following
opportunity for public review and
comment determine either:
(1) That the research or the clinical
investigation in fact satisfies the
conditions of 45 CFR 46.404, 46.405, or
46.406 under HHS regulations, and 21
CFR 50.51, 50.52, or 50.53 under FDA
regulations, or (2) that the following
conditions are met: (i) The research or
clinical investigation presents a
reasonable opportunity to further the
understanding, prevention, or
alleviation of a serious problem
affecting the health or welfare of
children; (ii) the research or clinical
investigation will be conducted in
accordance with sound ethical
principles; and (iii) adequate provisions
are made for soliciting the assent of
children and the permission of their
parents or guardians, as set forth in 45
CFR 46.408 and 21 CFR 50.55.
HHS received a request from Harbor-UCLA
Medical Center to review a
protocol entitled ‘‘A Multicenter,
Randomized Dose Response Study of
the Safety, Clinical and Immune
Response of DryvaxAdministered to
Children 2 to 5 Years of Age’’ pursuant
to the provisions of HHS regulations at
45 CFR 46.407. The sponsor of this
research, the National Institute of
Allergy and Infectious Diseases (NIAID),
NIH, proposes to study the safety and
immune response to Dryvax(vaccinia
virus vaccine), when administered to
children 2 to 5 years of age. This study
proposes to evaluate Dryvaxat its full,
licensed strength and at a 1:5 dilution,
in children enrolled in a number of
sites, including Harbor-UCLA Medical
Center and Cincinnati Children’s
Hospital Medical Center. Use of
Dryvaxin this protocol is being
performed under an FDA IND primarily
because there are no data to support the
efficacy of the 1:5 dilution of this
product in children. This protocol was
developed by NIAID in the context of
current HHS bioterrorism preparedness
plans, given the potential risk of
smallpox being used as a weapon of
bioterrorism, and has been approved by
two IRBs.
However, after reviewing this research
proposal, the Harbor-UCLA Medical
Center IRB determined that this study
could not be approved under 45 CFR
46.404, 46.405, or 46.406 but was
suitable for review under 45 CFR
46.407. Because this clinical
investigation is regulated by FDA,
FDA’s regulations at 21 CFR part 50,
subpart D, apply as well. The Harbor-UCLA
Medical Center IRB was unable to
assess the prospect of direct benefit to
the participants but found that the
research presented a reasonable
opportunity to further the
understanding, prevention or alleviation
of a serious problem affecting the health
or welfare of children. NIAID has not
initiated this clinical trial pending the
Secretary’s and Commissioner’s
determination. Experts in relevant
disciplines have reviewed this protocol
(see discussion below regarding access
to each expert’s report), but prior to the
Secretary and Commissioner making a
final determination, public review and
comment are hereby solicited pursuant
to HHS regulations at 45 CFR 46.407
and FDA regulations at 21 CFR 50.54. In
particular, comments are solicited on
the following questions: (1) What are the
potential benefits of the research, if any,
to the subjects and to children in
general; (2) what are the types and
degrees of risk that this research
presents to the subjects; (3) are the risks
to the subjects reasonable in relation to
the anticipated benefits, if any, to the
subjects, and the importance of the
knowledge that may reasonably be
expected to result; and (4) does the
research present a reasonable
opportunity to further the
understanding, prevention, or
alleviation of a serious problem
affecting the health or welfare of
children?
All written comments concerning this
matter should be submitted to FDA’s
Dockets Management Branch pursuant
to 21 CFR 10.20. Received comments
may be viewed on the FDA Web site at:
http://www.fda.gov/ohrms/dockets/
dockets/02n0466/02n0466.htm or may
be seen in the Dockets Management
Branch between the 9 a.m. and 4 p.m.,
Monday through Friday.
Materials available for review on the
OHRP Web page (available at http://
ohrp.osophs.dhhs.gov/dpanel/
dpindex.htm) include: The NIH
protocol, site-specific protocol
application reviewed by the Harbor-UCLA
Medical Center IRB, sample
parental permission document, relevant
package inserts, and reports of each of
the experts pursuant to HHS regulations
at 45 CFR 46.407 and FDA regulations
at 21 CFR 50.54. A paper copy of the
information referenced here is available
upon request.
Dated: October 23, 2002.
Lester M. Crawford,
Deputy Commissioner, FDA.
Dated: October 24, 2002.
Eve E. Slater,
Assistant Secretary for Health.
[FR Doc. 02–27769 Filed 10–30–02; 8:45 am]
BILLING CODE 4150–28–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. 02N–0454]
Agency Information Collection
Activities; Proposed Collection;
Comment Request; Notice of a Claim
for Generally Recognized as Safe
Exemption Based on a Generally
Recognized as Safe Determination
AGENCY: Food and Drug Administration,
HHS.
ACTION: Notice.
SUMMARY: The Food and Drug
Administration (FDA) is announcing an
opportunity for public comment on the

*the rest is blank and incomplete, FDA did not give a  third page
VerDate 0ct<09>2002 14:59 Oct 30, 2002 Jkt 200001 PO 00000 Frm 00025 Fmt 47


--
The silver-list is a moderated forum for discussion of colloidal silver.

Instructions for unsubscribing may be found at: http://silverlist.org

To post, address your message to: [email protected]

Silver-list archive: http://escribe.com/health/thesilverlist/index.html

List maintainer: Mike Devour <[email protected]>